Shares of Gilead Sciences rose 3% after its HIV prevention injection lenacapavir received a positive recommendation for approval in Europe. The CHMP endorsed the treatment for use as PrEP, potentially driving billions in revenue for the company. Investment firm Needham upgraded Gilead’s stock to ‘Buy’ with a price target of $133. The market sees this news as significant, though not a game-changer. Gilead Sciences is up 26.5% this year, trading near its 52-week high. Investors who bought shares 5 years ago now have a 56% return. Consider investing in enterprise software stocks leveraging generative AI capabilities for future growth.

Read more at StockStory Org.: Why Gilead Sciences (GILD) Stock Is Up Today